DEFINIENS INTRODUCES DEFINIENS TISSUEMAP 3.0

Automated Image Analysis Technology Supports the Development of Disease-Specific Biomarker Models and Companion Diagnostics

Munich / Morristown, NJ – October 27, 2008 – Definiens, the number one Enterprise Image Intelligence™ company, is unveiling the latest version of its image analysis application Definiens TissueMap 3.0. The application quantitatively assesses cellular structures and substructures in whole tissue sections and tissue microarrays, helping researchers discover, validate and measure new drug targets and disease-specific biomarkers.

The discovery of biomarker models and the increasing use of imaging technologies to acquire accurate measurements of disease parameters are significantly impacting the drug development process. However, the detailed quantification of key parameters, which is largely performed manually, remains a time-consuming and often inconsistent process.

Definiens TissueMap 3.0 accelerates image analysis by automatically identifying and quantifying nuclear, cytoplasmic and membrane markers in epithelial tumors and xenografts, providing researchers with fast, accurate and reproducible results. The application can handle both whole section slides and tissue microarrays and can differentiate between viable and necrotic tissue in xenografts. Implementing automated image analysis enables biotechnology and pharmaceutical companies to improve the prioritization of quality drug candidates by identifying poor candidates earlier in the drug development process and thereby realize substantial cost savings.

“Intelligent image analysis technology is vital to the development of predictive biomarker models and the advancement of translational research,” said Manfred Voglmaier, Vice President Business Development Life Sciences at Definiens. “Definiens TissueMap 3.0 supports researchers in extracting critical information from images throughout the drug discovery and development process.”

Definiens TissueMap 3.0 comes with a set of pre-defined tools to detect and quantify specific morphological or functional structures in tissues, such as tumor sections. The application is built on Definiens XD, Definiens’ multidimensional image analysis platform, which is highly flexible, scalable and supports a wide range of image acquisition devices.

Definiens TissueMap 3.0 will be introduced at Pathology Visions 2008 and will be commercially available worldwide starting November 2008.

Definiens in Life Sciences
Definiens supports Life Science organizations by automating image analysis on an enterprise level, from drug discovery to diagnostics. Its image analysis software enables pharmaceutical and biomedical companies to interpret vast numbers of digital images accurately and consistently. Definiens applications improve the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, helping organizations to advance translational research and personalized medicine.

About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel Laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Medical, Life Science, and Earth Science markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices in the United States. Further information is available at www.definiens.com.

Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.

Garry Clark
Ricochet PR
55 Broadway
New York, NY
10006
212-679-3300
GClark@ricochetpr.com

This release was published on openPR.